342
Participants
Start Date
October 20, 2023
Primary Completion Date
October 20, 2026
Study Completion Date
May 20, 2027
LBL-034 for Injection
Initial dose - MTD; Q2W; intravenous infusion
RECRUITING
Peking University People's Hospital, Beijing
NOT_YET_RECRUITING
Peking University Shougang Hospital, Beijing
RECRUITING
Shengjing Hospital of China Medical University, Shengyang
RECRUITING
The First Bethune Hospital of Jilin University, Changchun
RECRUITING
The First Affiliated Hospital of Wannan Medical College, Wuhu
RECRUITING
Qingdao Municipal Hospital, Qingdao
NOT_YET_RECRUITING
Institute of hematology & blood diseases hospital, chinese academy of medical sciences & peking union medical college, Tianjin
RECRUITING
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
RECRUITING
The First Affiliated Hospital of Ningbo University, Ningbo
RECRUITING
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
NOT_YET_RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
RECRUITING
The First Affiliated Hospital of Henan University, Luoyang
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Shenzhen Second People's Hospital, Shenzhen
RECRUITING
The Afliliated Hospital of Guizhou Medical Univeristy, Guiyang
RECRUITING
The Second Affiliated Hospital of Hainan Medical University, Haikou
RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an
RECRUITING
Shanxi Bethune Hospital, Taiyuan
Nanjing Leads Biolabs Co.,Ltd
INDUSTRY